Lin BioScience Inc

Lin BioScience Inc a drug development company develops therapies for oncology ophthalmology and metabolic diseases Its product pipeline includes LBS008 an oral therapy for dry agerelated macular degeneration Dry AMDand stargardt diseases STGD1 which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD LBS007 a natural nonATP CDC7 inhibitor for the treatment of cancers LBS002 an antitubulin to treat primary and metastatic brain tumors and LBS009 an oral therapy for the treatment of nonalcoholic fatty liver disease and type 2 diabetes The company is headquartered in Taipei Taiwan